Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 2/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.56 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PKLR | P30613 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954369 | 0.86 | ALDH1A1 (0.67) | GAAL3MBTL1MEN1KMT2ATNF | |
| SCHEMBL7956653 | 0.83 | GAA (0.67) | GAAL3MBTL1MEN1KMT2ATNF | |
| SCHEMBL20639653 | 0.83 | KDM4E (0.67) | KDM4ETP53 | |
| SCHEMBL2839187 | 0.81 | MEN1 (0.85) | GAAMEN1KMT2ALMNATSHR | |
| SCHEMBL2836518 | 0.81 | ALDH1A1 (0.72) | GAAL3MBTL1MEN1KMT2ALMNA | |
| SCHEMBL17241 | 0.81 | ALDH1A1 (0.63) | GAAL3MBTL1MEN1KMT2ALMNA | |
| SCHEMBL7956164 | 0.78 | LSS (0.70) | GAAL3MBTL1MEN1KMT2ALMNA | |
| SCHEMBL9344505 | 0.78 | ALDH1A1 (0.65) | LMNATSHRPKMPKLRALDH1A1 | |
| SCHEMBL31315858 | 0.78 | ALDH1A1 (0.65) | LMNATSHRPKMPKLRALDH1A1 | |
| SCHEMBL28818511 | 0.78 | HSD11B1 (0.60) | GAAMEN1KMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2010-08-26 | — | — | US | disclosed |
| US-7709488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2010-05-04 | — | — | US | disclosed |
| CN-100422182-C | Imidazopyridine derivatives as inducible NO-synthase inhibitors | ALTANA PHARMA AG (DE) | 2008-10-01 | — | — | CN | disclosed |
| EP-1670796-B1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NYCOMED GMBH (DE) | 2008-06-25 | — | — | EP | disclosed |
| US-20080021039-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG | 2008-01-24 | — | — | US | disclosed |
| US-7279488-B2 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NYCOMED GMBH (DE) | 2007-10-09 | — | — | US | disclosed |
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | ALTANA PHARMA AG (DE) | 2006-12-28 | — | — | US | disclosed |
| CN-1856495-A | Imidazopyridine Derivatives as Inducible NO-Synthase Inhibitors | ALTANA PHARMA AG (DE) | 2006-11-01 | — | — | CN | disclosed |
| EP-1670796-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030770-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | ALTANA PHARMA AG (DE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293302-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | GAA 3086/4885L3MBTL1 3580/4885MEN1 4540/4885 |
| US-20080021039-A1 | Imidazopyridine-derivatives as inducible no-synthase inhibitors | NOS2, NOS1, NOS3 | GAA 3086/4885L3MBTL1 3580/4885MEN1 4540/4885 |
| US-20100216790-A1 | IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTHASE INHIBITORS | NOS2, NOS1, NOS3 | GAA 3086/4885L3MBTL1 3580/4885MEN1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.